Superiority of haemocoagulase over other haemostats in bleeding management: A survey of medical practitioners

In 2024, India recorded over 30 million surgical procedures, with a significant majority, approximately 85%, performed in small to mid-sized hospitals, and only 15% conducted in corporate healthcare institutions. Bleeding remains a common and critical complication during surgeries, posing ongoing challenges for surgeons. According to the World Health Organization (WHO), intraoperative bleeding occurs in about 15% of all surgical cases and in up to 50% of cardiac surgeries. Postoperative bleeding affects up to 20% of patients, often resulting in extended hospital stays, increased treatment costs, and elevated risks of morbidity and mortality. These statistics underscore the urgent need for effective haemostatic agents that can control bleeding both during and after surgical procedures. Haemocoagulase has demonstrated superior haemostatic efficacy by significantly reducing perioperative bleeding without impairing the patient's coagulation function. It has established itself as a dependable component of clinical treatment protocols. This research undertakes a comprehensive review of scientific literature and a survey of physician perspectives to assess and validate the superiority of haemocoagulase as a haemostat. The convergence of findings from clinical studies, physician insights, and market analysis affirms haemocoagulase’s effectiveness, safety profile, and strong potential for market expansion. Overall, this study concludes that haemocoagulase stands out as a superior haemostatic agent compared to other available options.